Liraglutide – Next-Generation Antidiabetic Medication

Under development by Novo Nordisk, liraglutide is a member of a new class of antidiabetic medications called GLP-1 analogues. These mirror the effects of naturally produced glucagon-like peptide-1 (GLP-1), which includes glucose-dependent stimulation of insulin secretion, suppression of glucagon secretion, reduction of appetite and delay of food absorption.

Based primarily on data from the LEAD phase III trials, in May 2008 the company submitted an NDA to regulatory authorities in both the US and Europe. Filing in Japan is expected towards the end of the year.

THE GROWING BURDEN OF TYPE 2 DIABETES

Estimates from the World Health Organisation indicate that worldwide more than 170 million people have diabetes, of which type 2 diabetes accounts for about 90% of all cases. Prevalence is predicted to continue growing, fuelled in particular by rising rates of obesity, which is a major risk factor for impaired glucose tolerance leading to type 2 diabetes.

Although there have been important advances in the development of new therapies for type 2 diabetes, there remains a need for safe and effective antidiabetic medications. Currently available antidiabetic agents that boost insulin secretion or heighten insulin sensitivity can lead to patients developing extremely low blood glucose levels, or hypoglycaemia.

Because GLP-1 analogues act to lower blood glucose only when levels are raised and not during periods of normal or low blood-glucose concentrations, they should carry a much lower risk of hypoglycaemia than many established antidiabetic medications.

"LEAD" CLINICAL TRIALS DEMONSTRATE EFFICACY

The clinical effectiveness of Novo Nordisk’s liraglutide is being evaluated in a series of clinical trials as part of the Liraglutide Effect and Action in Diabetes, or LEAD programme, which consists of five randomised, double-blind controlled studies. These trials will assess the clinical effectiveness of liraglutide in some 3,800 patients with type 2 diabetes whose blood glucose is inadequately controlled with standard oral therapies.

The release of data from three of the five major phase III studies suggests that the addition of liraglutide to ongoing oral antidiabetic drugs can significantly improve glycaemic control in previously uncontrolled type 2 diabetics.

In LEAD 1, a trial in which 1026 patients receiving maximal dose glimepiride were subsequently randomised to treatment with liraglutide, rosiglitazone or placebo, liraglutide achieved statistically significantly better glucose control (HbA1c <7%) than rosiglitazone.

In LEAD 2, in which 1026 patients receiving maximal dose metformin were subsequently randomised to treatment with liraglutide, glimepiride or placebo, the improvement in HbA1c was similar in the liraglutide and glimepiride treatment arms.

In LEAD 5, a 581-patient study, the addition of liraglutide to metformin and glimepiride saw over 50% of patients achieving good glycaemic control (HbA1c <7%) with over 35% an HbA1c of < 6.5%. The reduction in HbA1c achieved with liraglutide was >0.2% better than that achieved in the active comparator arm (insulin glargine), a statistically significant difference.

These findings suggest that treatment with liraglutide is at least as good if not better than standard antidiabetic therapies. Liraglutide appears to be a well tolerated agent, with nausea the most common treatment-emergent adverse event to occur in the trials conducted to date.

GLP-1 ANALOGUES MAY AID WEIGHT LOSS IN OBESE PATIENTS

Data from the LEAD clinical trials programme show that in type 2 diabetic patients, treatment with liraglutide leads to significant weight loss. At the end of the LEAD studies, the difference in body weight between liraglutide and insulin glargine was on average 3.5kg, and 2kg and 4kg in comparison with rosiglitazone and glimepiride respectively. These findings are encouraging given that weight gain is a well recognised drawback of many established antidiabetic medications.

The potential to extend the use of liraglutide beyond diabetes to the treatment of obesity is clearly of interest, and supported by preclinical findings. In animal studies, administration of liraglutide was found to have a profound and persistent anorectic effect that resulted in weight loss.

If these findings are subsequently borne out in clinical trials in obesity then the anorectic actions of liraglutide may prove important in aiding weight loss not only in obese patients with type 2 diabetes but also in obese non-diabetic patients.

MARKETING COMMENTARY

At present type 2 diabetic patients poorly controlled with diet plus metformin and/or sulfonylureas usually receive additional oral medications, to which insulin is sometimes added, or insulin therapy alone. GLP-1 analogues offer an alternative approach for this patient population.

Analysts believe that if approved, Novo Nordisk’s liraglutide will help expand the market for GLP-1 analogues and increase treatment choice for type 2 diabetic patients. Byetta (exenatide), a drug with a similar mode of action to liraglutide, is already on the market as a treatment for type 2 diabetics inadequately controlled with standard therapies.

Click here for printable version